- September 30, 2021
- Posted by: Stratford Team
- Category: Business
Combined Company to Begin Trading on the Nasdaq Global Market® Under “PROC” and “PROCW” On September 30, 2021
Approximately $160 Million of Gross Proceeds Strategically Positions Procaps, a Leading Global Pharmaceutical Technology and Healthcare Company Based in Latin America, to Accelerate M&A Roll-Up Initiative and Expand New Product Categories in B2B & B2C Segments
Strong First Half 2021 Financial Results Position Procaps to Achieve Prior Full Year 2021 Guidance of Approximately $400 Million in Net Revenues and $105 Million of Adjusted EBITDA
Procaps Will be Led by Ruben Minski, Founder, Chairman of the Board and Chief Executive Officer of Procaps Group, and Current Executive Team Including Global Chief Financial Officer Patricio Vargas, President Dr. Camilo Camacho and Chairman of M&A Committee Alejandro Weinstein
BARRANQUILLA, Colombia, September 29, 2021–(BUSINESS WIRE)–Procaps Group, a leading integrated international healthcare and…
